Imatinib
Gleevec
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=211ef2da-2868-4a77-8055-1cb2cd78e24b
Gleevec 400 mg N = 818 Gleevec 800 mg N = 822 Progression-free survival (months) Median 18.9 23.2 ... Overall survival (months) 49.0 48.7 ... The response rate was 68.5% for the 400 mg group and 67.6% for the 600 mg group. ... Thirty-six months of Gleevec treatment significantly prolonged RFS compared to 12 months of Gleevec treatment with a hazard ratio of 0.46 (95% CI: 0.32, 0.65)
Gleevec USPI section 14.9, Table 26 and adjuvant Study 1 and Study 2
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT00009906
Phase III Randomized, Intergroup Trial Assessing the Clinical Activity Of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT00041197
A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec™) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT00116935
Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence
ClinicalTrials.gov API v2 record, retrieved 2026-11-07